Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Glial-Derived Neurotrophic Factor (GDNF) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| Glial-Derived Neurotrophic Factor (GDNF) Products under Development by Stage of Development | 7 | 1 |
| Glial-Derived Neurotrophic Factor (GDNF) Products under Development by Therapy Area | 8 | 1 |
| Glial-Derived Neurotrophic Factor (GDNF) Products under Development by Indication | 9 | 1 |
| Glial-Derived Neurotrophic Factor (GDNF) Pipeline Products Glance | 10 | 2 |
| Late Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Glial-Derived Neurotrophic Factor (GDNF) Products under Development by Companies | 12 | 2 |
| Glial-Derived Neurotrophic Factor (GDNF) Products under Development by Universities/Institutes | 14 | 2 |
| Glial-Derived Neurotrophic Factor (GDNF) Therapeutics Assessment | 16 | 7 |
| Assessment by Monotherapy/Combination Products | 16 | 1 |
| Assessment by Mechanism of Action | 17 | 2 |
| Assessment by Route of Administration | 19 | 2 |
| Assessment by Molecule Type | 21 | 2 |
| Glial-Derived Neurotrophic Factor (GDNF) Companies Involved in Therapeutics Development | 23 | 2 |
| NsGene A/S | 23 | 1 |
| UniQure N.V. | 24 | 1 |
| Glial-Derived Neurotrophic Factor (GDNF) Drug Profiles | 25 | 8 |
| AMT-090 Drug Profile | 25 | 1 |
| Drugs for Neurodegenerative Diseases Drug Profile | 26 | 1 |
| LAUR-301 Drug Profile | 27 | 1 |
| NsG-0301 Drug Profile | 28 | 1 |
| Recombinant Protein to Activate GDNF for Brain Ischemia Drug Profile | 29 | 1 |
| smilagenin Drug Profile | 30 | 3 |
| Glial-Derived Neurotrophic Factor (GDNF) Dormant Projects | 33 | 1 |
| Glial-Derived Neurotrophic Factor (GDNF) Featured News &Press Releases | 34 | 11 |
| Nov 28, 2013: Clinical trial launched to treat Sanfilippo B syndrome using gene therapy | 34 | 1 |
| Mar 26, 2013: Phytopharm Provides Strategic Review Update On On-going Phase II Clinical Trial Of Cogane | 34 | 1 |
| Feb 18, 2013: Phytopharm Announces Results From Parkinson s Disease Clinical Trial Of Cogane | 35 | 1 |
| Dec 18, 2012: Phytopharm Provides Update On Clinical Development Of Cogane In Amyotrophic Lateral Sclerosis | 36 | 1 |
| Apr 18, 2012: Phytopharm Completes Patient Recruitment In CONFIDENT-PD Phase II Cogane Study To Treat Parkinson s Disease | 37 | 1 |
| Apr 18, 2012: Phytopharm's Confirmatory Data Supports Effectiveness Of Phytopharm's Cogane In Amyotrophic Lateral Sclerosis | 38 | 1 |
| Jan 16, 2012: Phytopharm's Cogane Demonstrates Positive Results In Amyotrophic Lateral Sclerosis Study | 39 | 1 |
| Sep 29, 2011: European Commission Grants Orphan Drug Status For Phytopharm's Cogane For Treatment Of Amyotrophic Lateral Sclerosis | 40 | 1 |
| Jul 28, 2011: Phytopharm's Cogane Receives FDA Orphan Drug Status | 40 | 1 |
| Nov 17, 2010: Phytopharm Initiates Phase II Study Of Cogane In Patients With Parkinson's Disease | 41 | 1 |
| Jun 14, 2010: Phytopharm Receives FDA Approval To Begin Phase II Clinical Trial Of Cogane | 41 | 1 |
| Apr 20, 2009: Phytopharm Announces The Commencement Of Clinical Study of Cogane In Patients With Parkinson s Disease | 42 | 1 |
| Jan 21, 2008: Phytopharm Announces $1.16 million Funding For Cogane | 43 | 1 |
| Jun 05, 2007: Phytopharm plc Presents Cogane Data At 11th International Congress Of Parkinson s Disease And Movement Disorders | 43 | 1 |
| Nov 30, 2005: Phytopharm Announes That The Preliminary Trial Results Are Expected In December 2005 | 44 | 1 |
| Appendix | 45 | 2 |
| Methodology | 45 | 1 |
| Coverage | 45 | 1 |
| Secondary Research | 45 | 1 |
| Primary Research | 45 | 1 |
| Expert Panel Validation | 45 | 1 |
| Contact Us | 45 | 1 |
| Disclaimer | 46 | 1 |